BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN), a small molecule drug discovery and development company, announced today that Stephen R. Davis, previously Executive Vice President and Chief Operating Officer, has been appointed President, effective immediately. As part of on-going succession planning by Neurogen’s Board of Directors, he has also been selected as the eventual successor to William H. Koster, CEO of Neurogen.
